About Us


A young female grabs her abdomen, illustrating that she is experiencing stomach or gastrointestinal pain

Pediatric patients receiving the tumor necrosis factor (TNF) inhibitor adalimumab, combined with a low dose of methotrexate, a second immunosuppressant, to treat Crohn’s disease did better than those treated with adalimumab alone, according to findings of a PCORI-funded study published in Gastroenterology.

However, patients taking infliximab, another anti-TNF medication, had similar outcomes with or without methotrexate.

The results of The COMBINE Trial — led by Michael Kappelman, MD, MPH, from the School of Medicine at the University of North Carolina at Chapel Hill — provide important evidence to help answer questions about which medicines and combinations work best to treat Crohn’s disease in children. The lifelong inflammatory bowel disease is harder to treat in pediatric patients, but left untreated can impair growth, psychosocial development and puberty.

Posted: April 7, 2023

What's Happening at PCORI?

The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.

Subscribe to PCORI Emails


Hand pointing to email icon